Novo Nordisk receives Japanese approval for Victoza

The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk's drug Victoza for the

Victoza is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan. It is indicated as monotherapy or as an add-on to sulphonylurea (SU) in people with type 2 diabetes.

Mads Krogsgaard Thomsen, the executive vice president and chief science officer of Novo Nordisk, said: "The Japanese approval of Victoza represents a major advancement in the treatment of type 2 diabetes and an important milestone for Novo Nordisk.

"We are excited to pioneer the GLP-1 market in Japan, where we are convinced Victoza will prove to be a valuable treatment option for people with type 2 diabetes. The clinical studies conducted in Japan showed Victoza to provide superior glucose control with a low risk of hypoglycaemia."